Referências:   Villacampa G, Tung NM, Pernas S, Paré L, Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, del Monte-Millán M, Marín-Aguilera M, Brasó-Maristany F, Waks AG, Pascual T, Martínez-Sáez O, Vivancos A, Conte PF, Guarneri V, Dieci

Referências:   Joshi, U., Budhathoki, P., Gaire, S. et al. Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast. Breast Cancer Res Treat 200, 217–224 (2023). https://doi.org/10.1007/s10549-023-06959-3 ou

Referências:   Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced

Referências:   LBA500:  Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.    LBA506: 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHER

Referências:  Chung, S.H., de Geus, S.W.L., Shewmaker, G. et al. Axillary Lymph Node Dissection is Associated with Improved Survival Among Men with Invasive Breast Cancer and Sentinel Node Metastasis. Ann Surg Oncol (2023). https://doi.org/10.1245/s1043

Referências:   Gluz O, Nitz UA, Christgen M, et al. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Rando

Referências: Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer - Alison Laws, MD, MPH and Rinaa S. Punglia, MD, MPH - DOI: 10.1200/JCO.23.00455 Journal of Clinical Oncology -

Referências: Meirson T, Goldstein DA, Gyawali B, Tannock IF. Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer. Lancet Oncol. 2023 May 2:S1470-2045(23)00165-1. doi: 10.1016/S1470-2045(2

Referências: Chen T, Kharazmi E, Fallah M. Race and Ethnicity-Adjusted Age Recommendation for Initiating Breast Cancer Screening. JAMA Netw Open. 2023;6(4):e238893. doi:10.1001/jamanetworkopen.2023.8893 https://jamanetwork.com/journals/jamanetworkopen/ful

Referências: van Mackelenbergh MT, Loibl S, Untch M, Buyse M, Geyer CE Jr, Gianni L, Schneeweiss A, Conte P, Piccart M, Bonnefoi H, Jackisch C, Nekljudova V, Tang G, Valagussa P, Neate C, Gelber R, Poncet C, Squifflet P, Saad ED, Heinzmann D, Denkert C